3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About

2 months ago 11

David Jagielski, The Motley Fool

Thu, Apr 3, 2025, 6:00 AM 5 min read

"Buy and hold" is simply a elemental strategy for investors, but it tin beryllium a hard 1 to instrumentality to successful existent practice. That's due to the fact that galore radical privation to prime stocks and commercialized them, and consciousness similar they request to actively intervene to make important gains. But often, conscionable leaving your investments unsocial is the champion happening to do.

Take the 3 stocks listed beneath arsenic examples. A $1,000 concern into each of them 20 years agone would present beryllium worthy much than $100,000. Not each semipermanent concern volition crook retired that way, but investing a humble magnitude of wealth successful growth stocks and letting it beryllium tin beryllium your champion fiscal move.

Retirees connected the lookout for immoderate reliable dividend stocks tin find plentifulness of charismatic buying opportunities successful the markets today. The stocks listed present tin supply you with precocious yields and beryllium harmless investments to conscionable bargain and hide about, careless of what's happening successful the market.

Three stocks which I'd urge retirees see adding to their portfolios contiguous are AbbVie (NYSE: ABBV), ExxonMobil (NYSE: XOM), and Kimberly-Clark (NYSE: KMB). They person each generated affirmative gains this year, arsenic buyers person been flocking to them arsenic safe-haven investments. Here's a look astatine wherefore these tin beryllium large stocks to bargain and clasp for the agelong run.

Pharma banal AbbVie provides investors with an above-average output of 3.2%, which is much than treble the existent S&P 500 mean of 1.3%. The institution has been expanding its dividend for years, and that streak extends to much than 50 years if you see the clip erstwhile it was portion of Abbott Laboratories. Since the spinoff successful 2013, the dividend has skyrocketed by 310%.

AbbVie's concern is diverse, featuring products successful aggregate therapeutic areas, including oncology, immunology, aesthetics, and neuroscience. The lone 1 of those areas that didn't make affirmative year-over-year maturation successful 2024 was aesthetics (down 2%). However, arsenic request for value nonaccomplishment drugs continues to soar, determination could besides beryllium overmuch stronger request for Botox (which is portion of the segment), perchance making this a overmuch amended maturation catalyst successful the future.

AbbVie is simply a apical banal to ain successful healthcare. Trading astatine 17 times its aboriginal earnings, based connected expert expectations, it's besides a reasonably inexpensive enactment to adhd to your portfolio.

Another apical dividend maturation banal is lipid and state shaper ExxonMobil. Its existent output is simply a spot higher astatine 3.4%. It besides has an awesome streak going: The institution has boosted its payout for 42 consecutive years, with the latest being a 4% bump.